Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry

Journal of Analytical Toxicology

Volumn 33, Issue 5, 2009, Pages 243-252

  De Castro, Ana ^a,b   Concheiro, Marta ^a   Shakleya, Diaa M ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; ACETONITRILE; BENZOYLECGONINE; COCAINE; CODEINE; FORMIC ACID; METHADONE; MORPHINE; MORPHINE 6 ACETATE; OPIATE;

ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG METABOLISM; DRUG STABILITY; DRUG TISSUE LEVEL; FEMALE; HUMAN; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; OPIATE ADDICTION; PLACENTA; PREGNANCY; SOLID PHASE EXTRACTION;

EID: 68949099204     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/33.5.243     Document Type: Article

References (55)

1. M.A. Huestis and R.E. Choo. Drug abuse's smallest victims: in utero drug exposure. Forensic Sci. Int. 128: 20-30 (2002).
2. J. Luty, V. Nikolaou, and J. Bearn. Is opiate detoxification unsafe in pregnancy? J. Subst. Abuse Treat. 24: 363-367 (2003).
3. M. Behnke and F.D. Eyler. The consequences of prenatal substance use for the developing fetus, newborn, and young child. Int. J. Addict. 28: 1341-1391 (1993).
4. H.E. Jones, K.E. O'Grady, D. Malfi, and M. Tuten. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am. J. Addict. 17: 372-386 (2008).
5. B. Winklbaur, N. Kopf, N. Ebner, E. Jung, K. Thau, and G. Fischer. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 103: 1429-1440 (2008).
6. L.P. Finnegan. Treatment issues for opioid-dependent women during the perinatal period. J. Psychoactive Drugs 23: 191-201 (1991).
7. M. Daley, M. Argeriou, D. McCarty, J.J. Callahan, D.S. Shepard, and C.N. Williams. The impact of substance abuse treatment modality on birth weight and health care expenditures. J. Psychoactive Drugs 33: 57-66 (2001).
8. C. McMurtrie, K.D. Rosenberg, B.D. Kerker, J. Kan, and E.H. Graham. A unique drug treatment program for pregnant and postpartum substance-using women in New York City: results of a pilot project, 1990-1995. Am. J. Drug Alcohol Abuse. 25: 701- 713 (1999).
9. D.S. Svikis, J.H. Lee, N.A. Haug, and M.L. Stitzer. Attendance incentives for outpatient treatment: effects in methadone-and nonmethadone- maintained pregnant drug dependent women. Drug Alcohol Depend. 48: 33-41 (1997).
10. H.E. Jones, M.L. Velez, M.E. McCaul, and D.S. Svikis. Special treatment issues for women. In Methadone Treatment for Opioid Dependence, E.C. Strain and M.L. Stitzer, Eds. The Johns Hopkins University Press, Baltimore, MD, 1999, pp 251-280.
11. L. Burns and R.P. Mattick. Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. Drug and Alcohol Rev. 26: 487-492 (2007).
12. C.M. Murphy and M.A. Huestis. LC-ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3-beta-Dglucuronide, morphine-6-beta-D-glucuronide, and codeine-6- beta-D-glucuronide in human urine. J. Mass Spectrom. 40: 1412-1416 (2005).
13. R. Dams, C.M. Murphy, W.E. Lambert, and M.A. Huestis. Urine drug testing for opioids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 17: 1665-1670 (2003).
14. W.E. Wingert, M.S. Feldman, M.H. Kim, L. Noble, I. Hand, and J.J. Yoon. A comparison of meconium, maternal urine and neonatal urine for detection of maternal drug use during pregnancy. J. Forensic Sci. 39: 150-158 (1994).
15. E.M. Knight, J. Hutchinson, C.H. Edwards, B.G. Spurlock, U.J. Oyemade, A.A. Johnson, W.L. West, O.J. Cole, L.S. Westney, O.E. Westney, M. Manning, H. Laryea, and S. Jones. Relationships of serum illicit drug concentrations during pregnancy to maternal nutritional status. J. Nutr. 124(6 Suppl): 973S-980S (1994).
16. T.M. Doberczak, S.R. Kandall, and P. Friedmann. Relationships between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet. Gynecol. 81: 936-940 (1993).
17. R. Dams, C.M. Murphy, R.E. Choo, W.E. Lambert, A.P. De Leenheer, and M.A. Huestis. LC-atmospheric pressure chemical ionization- MS/MS analysis of multiple illicit drugs, methadone, and their metabolites in oral fluid following protein precipitation. Anal. Chem. 75: 798-804 (2003).
18. C. Eliopoulos, J. Klein, D. Chitayat, M. Greenwald, and G. Koren. Nicotine and cotinine in maternal and neonatal hair as markers of gestational smoking. Clin. Invest. Med. 19: 231-242 (1996).
19. F. Garcia-Bournissen, B. Rokach, T. Karaskov, and G. Koren. Methamphetamine detection in maternal and neonatal hair: implications for fetal safety. Arch. Dis. Child. Fetal Neonatal Ed. 92(5): F351-F355 (2007).
20. B.R. Brunet, A.J. Barnes, K.B. Scheidweiler, P. Mura, and M.A. Huestis. Development and validation of a solid-phase extraction gas chromatography-mass spectrometry method for the simultaneous quantification of methadone, heroin, cocaine and metabolites in sweat. Anal. Bioanal. Chem. 392: 115-127 (2008).
21. E.M. Ostrea, D.K. Knapp, A.I. Romero,M. Montes, and A.R. Ostrea. Meconium analysis to assess fetal exposure to nicotine by active and passive maternal smoking. J. Pediatr. 124: 471-476 (1994).
22. 9-THC in meconium by GC-MS. J. Anal. Toxicol. 29: 522-527 (2005).
23. T.R. Gray, D.M. Shakleya, and M.A. Huestis. Quantification of nicotine, cotinine, trans-3'-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography tandem mass spectrometry. J. Chromatogr. B 863: 107-114 (2008).
24. S.L. Kacinko, H.E. Jones, R.E. Johnson, R.E. Choo, and M.A. Huestis. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin. Pharmacol. Ther. 84(5): 604-612 (2008).
25. C.M. Moore, S. Brown, A. Negrusz, I. Tebbett, W. Meyer, and L. Jain. Determination of cocaine and its major metabolite, benzoylecgonine, in amniotic fluid, umbilical cord blood, umbilical cord tissue, and neonatal urine: a case study. J. Anal. Toxicol. 17: 62 (1993).
26. R.E. Winecker, B.A. Goldberger, I. Tebbett, M. Behnke, F.D. Eyler, M. Conlon, K. Wobie, J. Karlix, and R.L. Bertholf. Detection of cocaine and its metabolites in amniotic fluid and umbilical cord tissue. J. Anal. Toxicol. 21: 97-104 (1997).
27. D. Montgomery, C. Plate, S.C. Alder, M. Jones, J. Jones, and R.D. Christensen. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs. meconium. J. Perinatol. 26: 11-14 (2006).
28. J.S. Krouwer. Observations on comparisons of within-run and day-to-day precision. Clin. Chem. 27: 202 (1981).
29. J.S. Krouwer and R. Rabinowitz. How to improve estimates of imprecision. Clin. Chem. 30: 290-292 (1984).
30. B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75: 3019-3030 (2003).
31. Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. Off. J. Eur. Communities L 221: 8-36 (2002).
32. T.M. Annesley. Ion suppression in mass spectrometry. Clin. Chem. 49: 1041-1044 (2003).
33. R. Dams, M.A. Huestis, W.E. Lambert, and C.M. Murphy. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J. Am. Soc. Mass Spectrom. 14: 1290-1294 (2003).
34. P.J. Taylor. Matrix effects: the Achilles heel of quantitative highperformance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 38: 328-334 (2005).
35. M. Concheiro, A. de Castro, O. Quintela, A. Cruz, and M. López- Rivadulla. Determination of illicit and medicinal drugs and their metabolites in oral fluid and preserved oral fluid by liquid chromatography- tandem mass spectrometry. Anal. Bioanal. Chem. 391: 2329-2338 (2008).
36. E.J. Rook, M.J. Hillebrand, H. Rosing, J.M. van Ree, and J.H. Beijnen. The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 824: 213-221 (2005).
37. R. Gottardo, A. Polettini, D. Sorio, J.P. Pascali, F. Bortolotti, E. Liotta, and F. Tagliaro. Capillary zone electrophoresis (CZE) coupled to time-of-flight mass spectrometry (TOF-MS) applied to the analysis of illicit and controlled drugs in blood. Electrophoresis 29: 4078-4087 (2008).
38. M.J. Bogusz, R.D. Maier, K.D. Krüger, and U. Kohls. Determination of common drugs of abuse in body fluids using one isolation procedure and liquid chromatography-atmospheric-pressure chemical-ionization mass spectrometry. J. Anal. Toxicol. 22: 549-558 (1998).
39. K.R. Allen, R. Azad, H.P. Field, and D.K. Blake. Replacement of immunoassay by LC tandem mass spectrometry for the routine measurement of drugs of abuse in oral fluid. Ann. Clin. Biochem. 42: 277-284 (2005).
40. M.R. Moeller, P. Fey, and R. Wennig. Simultaneous determination of drugs of abuse (opiates, cocaine and amphetamine) in human hair by GC/MS and its application to a methadone treatment program. Forensic Sci. Int. 63: 185-206 (1993).
41. S. Hegstad, H.Z. Khiabani, L. Kristoffersen, N. Kunoe, P.P. Lobmaier, and A.S. Christophersen. Drug screening of hair by liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 32: 364-372 (2008).
42. W. Luck, H. Nau, R. Hansen, and R. Steldinger. Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. Dev. Pharmacol. Ther. 8: 384-395 (1985).
43. I. Martin, M.A. Lopez-Vilchez, A. Mur, O. Garcia-Algar, S. Rossi, E. Marchei, and S. Pichini. Neonatal withdrawal syndrome after chronic maternal drinking of mate. Ther. Drug Monit. 29: 127-129 (2007).
44. O. Garcia-Algar, M.A. Lopez-Vilchez, I. Martin, A. Mur, M. Pellegrini, R. Pacifici, S. Rossi, and S. Pichini. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clin. Toxicol. 45: 295-298 (2007).
45. O. Garcia-Algar, O. Vall, F. Alameda, C. Puig, M. Pellegrini, R. Pacifici, and S. Pichini. Prenatal exposure to arecoline (areca nut alkaloid) and birth outcomes. Arch. Dis. Child. Fetal Neonatal Ed. 90: F276-F277 (2005).
46. P.S. Ramsey, M.B. Vaules, G.M. Vasdev, W.W. Andrews, and K.D. Ramin. Maternal and transplacental pharmacokinetics of azithromycin. Am. J. Obstet. Gynecol. 188: 714-718 (2003).
47. T.N. Nanovskaya, S.V. Deshmukh, I.A. Nekhayeva, O.L. Zharikova, G.D. Hankins, and M.S. Ahmed. Methadone metabolism by human placenta. Biochem. Pharmacol. 68: 583-591 (2004).
48. M.A. Peters, M. Turnbow, and D. Buchenauer. The distribution of methadone in the nonpregnant, pregnant and fetal rat after acute methadone treatment. J. Pharmacol. Exp. Ther. 181: 273-278 (1972).
49. K. Srinivasan, P. Wang, A.T. Eley, C.A. White, and M.G. Bartlett. Liquid chromatography-tandem mass spectrometry analysis of cocaine and its metabolites from blood, amniotic fluid, placental and fetal tissues: study of the metabolism and distribution of cocaine in pregnant rats. J. Chromatogr. B 745: 287-303 (2000).
50. H.O. Morishima, R.A. Whittington, Y. Zhang, and T.B. Cooper. The disposition of cocaethylene in rat maternal, placental, and fetal compartments. Am. J. Obstet. Gynecol. 180: 1289-1296 (1999).
51. M.R. Syme, J.W. Paxton, and J.A. Keelan. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. 43: 487-514 (2004).
52. A.C. Enders and T.N. Blankenship. Comparative placental structure. Adv. Drug Deliv. Rev. 38: 3-15 (1999).
53. G.W. Mihaly and D.J. Morgan. Placental drug transfer: effects of gestational age and species. Pharmacol. Ther. 23: 253-266 (1983).
54. E.M. van der Aa, J.H. Peereboom-Stegeman, J. Noordhoek, F.W. Gribnau, and F.G. Russel. Mechanisms of drug transfer across the human placenta. Pharm. World Sci. 20: 139-148 (1998).
55. H. Schneider. Placental transport function. Reprod. Fertil. Dev. 3: 345-353 (1991).